Race Oncology Ltd. (RAC)

Overview

Race Oncology Limited is a pivotal player in the biotechnology industry, dedicated to the advancement of cancer care on a global scale. Initially known as Coronado Resources Limited, the company underwent a name change to Race Oncology Limited in July 2016, marking a new era in its commitment to combatting cancer. Since its inception in 2011, the company has been headquartered in Sydney, Australia, positioning itself as a clinical stage biotechnology entity. Race Oncology's strategy encompasses a comprehensive approach to addressing the myriad of unmet needs within oncology, leveraging collaborations with renowned institutions such as City of Hope, MD Anderson, Sheba City of Health, and UNC School of Medicine to bolster its efforts. This broad-reaching engagement underlines the company's dedication not only to innovation in cancer treatment but also to integrating its offerings into the global cancer care ecosystem.

Products and Services

Lead Product - Bisantrene: At the core of Race Oncology's innovative portfolio is bisantrene, a small molecule anthracene chemotherapeutic agent, which symbolizes the company's flagship cancer treatment solution. Through meticulous development, bisantrene is positioned to cater to the significant unmet needs of oncology patients, with a keen focus on delivering not just anti-cancer efficacy but also cardio-protection. This dual-benefit approach aims to elevate bisantrene above traditional chemotherapeutic agents, potentially offering a more comprehensive treatment modality for patients.

m6A RNA Pathway Investigation: A groundbreaking element of Race Oncology's research endeavors revolves around the m6A RNA pathway, where bisantrene has been identified as a potent inhibitor of the FTO (Fat mass and obesity-associated) protein. This exploration is predicated on independent research findings and represents a pivotal aspect of the company's mission to diversify the applications of bisantrene. By delving into the intricate dynamics of how bisantrene and newly synthesized molecules can modulate this pathway, Race Oncology is at the forefront of unveiling novel therapeutic strategies that could redefine cancer treatment paradigms.